Singapore, June 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National Cancer Centre
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Toh Chee Keong
Aaron Tan
Dr Ross Soo
Published by HT Digital Content Services with permission from Health Daily Digest....